PRPH (ProPhase Labs) ROE % Adjusted to Book Value: -500.68% (As of Dec. 2025)


What is ProPhase Labs ROE % Adjusted to Book Value?

ProPhase Labs PRPH -4.61% ROE % Adjusted to Book Value is -500.68% as of Dec. 2025. The stock has 4 warning signs investors should review.

ProPhase Labs's ROE % for the quarter that ended in Dec. 2025 was -570.78%. ProPhase Labs's PB Ratio for the quarter that ended in Dec. 2025 was 1.14. ProPhase Labs's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -500.68%.

ProPhase Labs ROE % Adjusted to Book Value Related Terms

ProPhase Labs ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for ProPhase Labs's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProPhase Labs ROE % Adjusted to Book Value Chart

ProPhase Labs Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.59 12.33 -18.00 -61.07 -238.15

ProPhase Labs Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -196.23 127.21 -94.88 -107.95 -500.68

PRPH vs NSTM, IDTA, IVRO: ROE % Adjusted to Book Value Comparison

For the Diagnostics & Research subindustry, ProPhase Labs's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ProPhase Labs ROE % Adjusted to Book Value vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, ProPhase Labs's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where ProPhase Labs's ROE % Adjusted to Book Value falls into.


ProPhase Labs ROE % Adjusted to Book Value Calculation

ProPhase Labs's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-271.49% / 1.14
=-238.15%

ProPhase Labs's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-570.78% / 1.14
=-500.68%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -500.68% mean?
ProPhase Labs (PRPH) has a ROE % Adjusted to Book Value of -500.68% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on ProPhase Labs and its competitors.
Is ProPhase Labs' ROE % Adjusted to Book Value too high?
ProPhase Labs' current ROE % Adjusted to Book Value is -500.68%.
How does ProPhase Labs' ROE % Adjusted to Book Value compare to NSTM and IDTA?
ProPhase Labs' ROE % Adjusted to Book Value of -500.68% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Diagnostics & Research company?
A good ROE % Adjusted to Book Value depends on the Medical Diagnostics & Research industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on ProPhase Labs and its competitors. ProPhase Labs's current ROE % Adjusted to Book Value is -500.68%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProPhase Labs stock overvalued right now?
Based on GuruFocus' analysis, ProPhase Labs (PRPH) is currently considered Possible Value Trap. The stock's GF Value™ is $0.65, compared to a current price of $0.09 — trading 86% below its estimated fair value. The current ROE % Adjusted to Book Value is -500.68%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For ProPhase Labs (PRPH), the current ROE % Adjusted to Book Value is -500.68% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ProPhase Labs Business Description

Address 626 RXR Plaza, 6th Floor, Uniondale, NY, USA, 11556
ProPhase Labs Inc oriented and diversified next generation biotech, genomics and consumer products company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing. It offer whole genome sequencing and related services. It maintain two operating segments: diagnostic services (which includes its COVID-19 and other diagnostic testing services) and consumer products. It generates majority of revenue from consumer products segment which engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services.